Back to Newsroom
Back to Newsroom

SHAREHOLDER ALERT: PLAN FLDM MESO: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

Thursday, 22 October 2020 01:45 PM

The Law Offices of Vincent Wong

Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / October 22, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Anaplan Inc. (NYSE:PLAN)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/anaplan-inc-loss-submission-form?prid=10389&wire=1
Lead Plaintiff Deadline: October 23, 2020
Class Period: November 21, 2019 - February 26, 2020

Allegations against PLAN include that: (1) the Company was undergoing sales organization and execution challenges; (2) these organizational challenges were causing the Company to miss on closing very important large deals; and (3) as a result, Anaplan's financial guidance for "calculated billings growth" was baseless and unattainable. Further, while in possession of this material non-public information, Anaplan insiders dumped approximately $30 million worth of Anaplan stock at artificially inflated prices.

Fluidigm Corporation (NASDAQ:FLDM)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/fluidigm-corporation-loss-submission-form?prid=10389&wire=1
Lead Plaintiff Deadline: November 20, 2020
Class Period: February 7, 2019 - November 5, 2019

Allegations against FLDM include that: (1) Fluidigm was experiencing longer sales cycles; (2) as a result, Fluidigm's revenue was reasonably likely to decline; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Mesoblast Limited (NASDAQ:MESO)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/mesoblast-limited-loss-submission-form?prid=10389&wire=1
Lead Plaintiff Deadline: December 7, 2020
Class Period: April 16, 2019 - October 1, 2020

Allegations against MESO include that: (1) comparative analyses between Mesoblast's Phase 3 trial and three historical studies did not support the effectiveness of the Company's lead product candidate, remestemcel-L, for steroid refractory acute graft versus host disease due to design differences between the four studies; (2) as a result, the US Food and Drug Administration was reasonably likely to require further clinical studies; (3) as a result, the commercialization of remestemcel-L in the U.S. was likely to be delayed; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]

SOURCE: The Law Offices of Vincent Wong

Topic:
Lawsuits
Back to newsroom
Back to Newsroom
Share by: